Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression

MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/ -- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Urological Association (AUA) in Anaheim, California. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. An NDA for satraplatin is currently under priority review by the U.S. FDA.

"Patients with metastatic hormone-refractory prostate cancer frequently suffer from substantial pain associated with bone metastases. Thus, pain control for these patients constitutes a major challenge and is an important goal when caring for them," said Oliver Sartor, M.D., Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Associate Professor at Harvard Medical School, Boston, MA, and principal investigator of the SPARC trial, who is presenting the satraplatin data today. "In addition to the very encouraging results for progression-free survival demonstrating a 33% lower risk of progression compared to control, it is exciting to see that the SPARC trial results show that treatment with satraplatin also results in a statistically significant improvement in time to pain progression."

Data presented today showed that the median time to pain progression was 66.1 weeks for the satraplatin arm compared with 22.3 weeks for
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

Post Your Comments:
(Date:11/6/2009)... 6 Chimerix, Inc., a biopharmaceut...therapeutics to address life-threatening diseases,...ny,s lead antiviral compound, CMX001, to the World...ecurity Initiative (GHSI). CMX001 is a broad-spec...ment of smallpox, as well as other serious viral i...
(Date:11/6/2009)...NexBio Inc., in collaboration with scientists at t...), St. Louis University, and the University of Hon...icles in the peer-reviewed journal PLoS ONE. Thes...se ® ) may play a potentially important role ...nfluenza A(H1N1) and drug-resistant influenza. ,...
(Date:11/6/2009)... -- , - Trial Will Compare NXL103 With Le...lti-Resistant Staphylococcus Aureus (MRSA) Infecti...l company focused on the discovery and,development...nificant global,problem of microbial resistance, a...terial NXL103 (flopristin/linopristin), has starte...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 1Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 2Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 3Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 4China Biotics Inc Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results 12968 1China Biotics Inc Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results 12968 2
...s; 11 Breast Cancer Studies; 9 Targeted,Agent Stud...all/ -- Lilly,Oncology will unveil 76 studies at t...Clinical Oncology (ASCO) in Chicago, Ill. from,Jun...ta on,GEMZAR(R) (gemcitabine HCl for injection), A...in, an investigational, oral, targeted,therapy. Th...
...ia--(BUSINESS WIRE)--May 23, 2007 -,ProtoKinetix I...studies conducted by ITTEC Stem, Inc. at the Unive...AAGP(TM) in the cryopreservation,process for stem ...ecule in the rapidly expanding stem cell industry....on human embryonic stem cells., Using standard cry...
Other Medicine Technology:Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007 2ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2
(Date:11/8/2009)...he battle is won," said Dr. Charmaine Yoest. ,... a vote of 240-194, the Stupak-Ellsworth-Pitts-Kap...t abortion mandates and funding in HR 3962 passed ...e Action President and CEO Dr. Charmaine Yoest sai... the pro-life Americans across this country who ha...
(Date:11/8/2009)...e-USNewswire/ -- The following was released today ...recta Nex. ,, Mr. Terry and his associates fro...ild-killing by abortion out of any health care bil...reat first step to victory -- a touchdown in the f...d of us. Our rejoicing must be tempered by reality...
(Date:11/7/2009)...e-USNewswire/ -- Karen Ignagni, President and CEO ...ed the following statement today on House passage ... comprehensive health care reform, and we have con...e overhaul of how health insurance is provided. Ea...elimination of pre-existing condition exclusions, ...
(Date:11/7/2009)...-- Calling this a "defining moment" for the Americ... James Rohack, M.D., today addressed medical stude...al specialty societies at the opening of the AMA,s...ystem reform will top the agenda. ,, (Logo: h...O ) ,, "Over the next 72 hours, this AMA Hous...
(Date:11/7/2009)...e-USNewswire/ -- Speaker Nancy Pelosi and Democrat...n following a Democratic Whip meeting with Preside... Speaker,s opening remarks: ,, "Thank you very... us to receive the President of the United States ...r vote and making progress for the American people...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...ity of implanted cardiac pacemakers and defibrilla... devices still tended to malfunction// at times. ...the pacemaker or the defibrillator reliability of ...a malfunctioning heart. Dr. William H. Maise...
... Nanaimo, B.C. man, George Cook father Cheryle Coo... be launched against the hospital. His death was m...treatment. It took seven hours before he was seen ...r's home to Nanaimo Regional General Hospital suff...
...ealed that women aged 60 and younger have an incre...tack compared to others. The results of the study ...th-care costs of such patients when compared to he...e. According to lead author Dr. Susmita Mallik...
... organization has undertaken a campaign to elimina... at the sixth International Multidisciplinary Cong...nital Infection and Neoplasia (EUROGIN) held in Pa... Government is a non-profit, bi-partisan organizat...
...a novel way to verify that the complete cancer has...ed report is published in the May issue of Radiolo...xplored region of the electromagnetic spectrum--th...ogy has the potential to eliminate the need for mu...
... survey it was found that pet owners are the main ...f human obesity pet obesity have propped up. //Acc...imals could cause as much suffering as those that ...oner about the number of obese pets that visited t...
Other Medicine News:Health News:Reliability of Pacemakers and Defibrillators to be Improved 2Health News:Depression Accompanies Heart Attacks in Younger Women 2Health News:Campaign to Eliminate Cervical Cancer 2Health News:Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments 2
Chagatest ELISA
...with recombinant technology, that have been fully ...ble of detecting the different types of T.cruzi th...o acid sequences repeated in tandem. SAPA (shed ac... of the infection, it reacts with 93% of the patie...
T. cruzi IgG CELISA
Chagas Quick Step
Medicine Products: